Lendeckel; Uwe

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lendeckel; Uwe.The latest application filed is for "method for activating regulatory t-cells".

Company Profile

0.5.9

Lendeckel; Uwe - Greifswald DE
Lendeckel; Uwe - Magdeburg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method For Activating Regulatory T-cells App 20110117069 - Ansorge; Siegfried ; et al.	2011-05-19
Combined use of enzyme inhibitors and of pharmaceutical compositions thereof Grant 7,803,776 - Ansorge , et al. September 28, 2	2010-09-28
Use of enzyme inhibitors of aminopeptidase N and/or dipeptidylpeptidase IV Grant 7,683,034 - Ansorge , et al. March 23, 2	2010-03-23
Combinations of enzyme inhibitor-containing preparations and the use thereof Grant 7,485,626 - Ansorge , et al. February 3, 2	2009-02-03
Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors Grant 7,425,532 - Ansorge , et al. September 16, 2	2008-09-16
Combined use of enzyme inhibitors and of pharmaceutical compositions thereof App 20070249541 - Ansorge; Siegfried ; et al.	2007-10-25
Combinations of enzyme inhibitors and the use thereof Grant 7,229,969 - Ansorge , et al. June 12, 2	2007-06-12
Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts App 20070042938 - Ansorge; Siegfried ; et al.	2007-02-22
Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors App 20060211602 - Ansorge; Siegfried ; et al.	2006-09-21
Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states App 20060040850 - Ansorge; Siegfried ; et al.	2006-02-23
Vital mammalian heart tissue cells maintained ex vivo, processes of the collection and cultivation thereof and their use App 20050239039 - Goette, Andreas ; et al.	2005-10-27
Combinations of enzyme inhibitor-containing preparations and the use thereof App 20050014699 - Ansorge, Siegfried ; et al.	2005-01-20
Use of enzyme inhibitors of the dipeptidypeptidase iv (ec3.3.14.5) in addition to the aminopeptidase n (ec 3.4.11.2), individually or in a combination thereof, and pharmaceutical preparations thereof for the prevention and/or therapy of ischaemia-caused acute and chronic neurodegenerative process an App 20040147434 - Ansorge, Siegfried ; et al.	2004-07-29
Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and a prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type I according to the gell and coombs classification and for the treatment and prevention of dermatological d App 20040132639 - Ansorge, Siegfried ; et al.	2004-07-08

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.